(Q38957939)

8 September 2017

title

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases (English)

1 reference

8 September 2017

main subject

alectinib hydrochloride

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

Tatsushi Kodama

1

1 reference

8 September 2017

Masami Hasegawa

2

1 reference

8 September 2017

Kenji Takanashi

3

1 reference

8 September 2017

Yuji Sakurai

4

1 reference

8 September 2017

Osamu Kondoh

5

1 reference

8 September 2017

Hiroshi Sakamoto

6

1 reference

8 September 2017

publication date

10 September 2014

1 reference

Cancer Chemotherapy and Pharmacology

8 September 2017

published in

1 reference

8 September 2017

volume

74

1 reference

8 September 2017

issue

5

1 reference

8 September 2017

page(s)

1023-1028

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

Treating ALK-positive lung cancer--early successes and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

P-glycoprotein contributes to the blood-brain, but not blood-cerebrospinal fluid, barrier in a spontaneous canine p-glycoprotein knockout model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2578-6

10.1007/S00280-014-2578-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

8 September 2017

1032668845

0 references

Fatcat ID

release_43o4224v3ffq3ch3z44prtrtym

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/43o4224v3ffq3ch3z44prtrtym

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference